Table 2.
Inflammatory markers in plasma
| Median baseline levels (q1–q3) (pg mL−1) | Median level after 13-week treatment | Number of patients with a positive response after the 13-week treatment | Median level at 8 weeks after treatment stopped (pg mL−1) | P | |
|---|---|---|---|---|---|
| sCD14 | 1270 (905–1450) | 1030 (884–1140) | 7/10 | 1280 (993–1440) | NS |
| TNF-α | 1.45 (1.25–1.9) | 1.35 (1.20–1.8) | 7/10 | 1.25 (1.00–1.85) | NS |
| sTNFRI | 716 (694–864) | 685 (640–814) | 7/10 | 768 (716–857) | NS |
| sTNFRII | 1513 (1214–1853) | 1304 (1130–1626) | 8/10 | 1268 (1020–1549) | NS |
| CCL2 | 152 (134–175) | 158 (131–178) | 5/10 | 148 (122–164) | NS |
| CCL8 | 373 (143–377) | 312 (106–345) | 3/3 | — | NS |
Abbreviations: NS, not significant; s, soluble; TNF, tumour necrosis factor.